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	 New	 series	 of	 arylthiadiazole	 hydrazinecarboxamides	 (5a‐e)	 have	 been	 synthesized	 by
hydrazinolysis	 of	 carbamates	 (4a‐e)	 and	 spectrally	 characterized.	 The	 new	 candidates	 have
been	screened	for	their	anticonvulsant	and	immunomodulatory	activities.	Compound	5e	was
the	most	potent	anticonvulsant	candidate	as	it	showed	100%	protection	against	both	maximal
electroshock	 seizure	 (MES)	 and	 subcutaneous	 pentylenetetrazole	 (scPTZ)	 screens	 without
neurotoxicity	 at	 100	 mg/kg	 (0.318	 mmol/kg).	 With	 respect	 to	 immunomodulation,
compounds	5a	and	5d	revealed	immunostimulatory	activity	while	compounds	5b,	5c,	and	5e
had	immunosuppressive	responses	based	on	ELISA	detection	of	IgM	and	IgG	levels,	counting
the	total	mesenteric	lymph	nodes	lymphocytes,	and	histo‐pathological	examinations.	
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1.	Introduction	
	
Disorders	 of	 immune	 system,	 autoimmunity	 or	 immune‐
deficiency,	 lead	 to	 many	 devastating	 diseases.	 The	 immune	
system	 can	 be	 manipulated	 specifically	 by	 vaccination	 or	
nonspecifically	 by	 immunomodulation,	 which	 includes	 both	
immunostimulatory	 and	 immunosuppressive	 agents	 [1].	
Immunostimulatory	agents	 capable	of	 enhancing	host	defense	
mechanisms	 to	 provide	 protection	 against	 infections	 and	 to	
overcome	 immunodeficiency	 cases.	 Immunosuppressant	
agents,	which	manage	autoimmunity,	are	widely	used	in	trans‐
plantation,	inflammation,	and	many	allergic	manifestations	[2].	
Noteworthy,	many	 immune	diseases	 like	HIV	 and	 rheumatoid	
arthritis	are	still	looking	for	better	control.	
Heterocyclic	 compounds	 enclosing	 five‐membered	 rings	
gained	importance	due	to	their	adaptable	biological	properties.	
Among	these	moieties,	thiadiazoles	exhibited	a	wide	variety	of	
biological	 activities	 like	 antimicrobial	 [3],	 anti‐inflammatory	
[4],	 anticancer	 [5],	 anticonvulsant	 [6],	 antioxidant,	 radio‐
protective	[7],	and	anti‐leishmanial	[8].	They	are	represented	in	
pharmaceutical	 market	 via	 several	 drugs	 like	 carbonic	
anhydrase	 inhibitors	 (e.g.	 acetazolamide	 and	methazolamide),	
also	 in	 the	 third	 and	 fourth	 generation	 cephalosporins	 (e.g.	
Cefazolin	 and	Cefazedon)	 (Figure	1).	 Thiadiazole	 is	 a	 constra‐
ined	 pharmacophore	 with	 hydrogen	 binding	 domain	 and	
electron	donor	system.	it	is	occurring	in	nature	in	four	isomeric	
forms	(1,2,3‐thiadiazole,	1,2,5‐thiadiazole,	1,2,4‐thiadiazole	and	
1,3,4‐thiadiazole)	 where	 1,3,4‐thiadiazole	 isomer	 is	 the	 most	
investigated	one	[9].	
Despite	the	plethora	of	activities	that	have	been	correlated	
to	 thiadiazole	 derivatives,	 immune	 related	 responses	 still	 at	
very	primitive	stage	or	by	other	words	 it	 is	 the	 least	explored	
activity.	 The	 most	 important	 immune	 active	 thiadiazole	
derivative	is	YM‐58483	(Figure	2).	It	is	commercially	available	
and	 used	 mainly	 in	 research	 work	 as	 immunosuppressant.	
Many	mechanisms	were	 suggested	 for	 the	 biological	 effect	 of	
YM‐58483	like	inhibiting	both	Ca2+	influx	and	interleukin‐2	(IL‐
2)	 production	 in	 lymphocytes	 [10].	 In	 addition,	 it	 inhibits	 T	
helper	 type	 2	 (Th2)	 cytokine	 production	 [11].	 Other	 thiadi‐
azole‐carboxamide	 derivatives	 have	 been	 reported	 with	
immunomodulatory	activity	 like	 compounds	 I	 [12]	and	 II	 [13]	
(Figure	2)	where	1,3,4‐thiadiazole	was	connected	to	hydro‐	
El‐Behairy	et	al.	/	European	Journal	of	Chemistry	5	(3)	(2014)	488‐496	 489	
 
	
 
	
Figure	1.	Market	available	1,3,4‐thiadiazole	containing	drugs.
	
	
 
	
Figure	2.	Immunomodulatory	thiadiazole	and	hydrazinecarboxamide	derivatives.
	
	
 
	
Figure	3.	The	joint	pharmacophoric	model.
	
	
phobic	 domain	 via	 carboxamide	 moiety.	 Noteworthy,	
hydrazinecarboxamide	 derivatives	 are	 also	 still	 uncharted	 as	
immunomodulatory	 agents	 despite	 their	 other	 effective	
biological	 profiles	 [14].	 Compound	 III	 (Figure	2)	 is	 one	of	 the	
very	 rare	 instances	 of	 immunomodulatory	 hydrazinecarbox‐
amide	derivatives	[13].	
In	 the	present	work,	we	were	motivated	 to	discover	more	
about	 thiadiazoles	 and	 hydrazinecarboxamides	 as	 immune‐
modulatory	 agents.	 However,	 the	 shortage	 of	 reported	 data	
relating	 thiadiazoles	 and	 hydrazinecarboxamides	 to	 immune	
response	 pushed	 us	 to	 design	 very	 simple	 candidates	 which	
could,	 in	 the	future,	act	as	prototypic	model	and	subjected	 for	
further	modifications	to	improve	the	activity.	Thus,	joint	model	
of	 immune	active	pharmacophoric	moieties	has	been	designed	
(Figure	 3).	 The	 pharmacophoric	 model	 contains	 thiadiazole,	
hydrazinecarboxamide,	 carboxamide	 (as	 a	 part	 of	 hydrazine	
carboxamide	scaffold)	and	hydrophobic	domain	(R).	Then	very	
concise	series,	enough	to	act	as	a	scratch,	has	been	synthesized	
and	 pharmacologically	 evaluated	 as	 immunomodulators.	 In	
addition,	 the	 well‐documented	 anticonvulsant	 activity	 of	
thiadiazoles	 and	 hydrazinecarboxamides	 has	been	 studied	 for	
the	novel	candidates.	
2.	Experimental	
	
2.1.	Materials	
	
2.1.1.	Animals	
	
Swiss	 albino	 mice	 weighing	 18‐25	 gram	 were	 used	 for	
evaluation	 of	 the	 anticonvulsant,	 neurotoxicity,	 humoral	 and	
cellular	 immune	 responses,	 as	 well	 as	 histopathological	
examination	of	 the	 liver.	 The	 animals	used	 in	 this	 study	were	
purchased	 from	 Animals	 House	 Colony	 of	 the	 National	
Research	 Centre,	 Cairo,	 Egypt.	 Animals	 were	 housed	 under	
standardized	 conditions	 (room	 temperature	 23±2	 °C;	 relative	
humidity	55±5%;	12	h	light/dark	cycle)	and	had	free	access	to	
tap	 water	 and	 standard	 mice	 chow	 throughout	 the	 whole	
experimental	 period.	 Anesthetic	 procedures	 complied	 with	
ethical	 guidelines	 approved	 by	 the	 Ethical	 Committee	 of	 the	
Federal	Legislation	and	National	Institutes	of	Health	Guidelines	
in	USA	and	were	approved	by	the	Medical	Ethical	Committee	of	
the	National	Research	Centre	in	Egypt.	
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Scheme	1
	
	
2.1.2.	Chemicals	and	drugs	
	
Pentylenetetrazole	 (PTZ),	 tween‐20	 and	 o‐phenylene	
diamine	 (OPD)	 were	 purchased	 from	 Sigma	 (St.	 Louis,	 Mo,	
USA),	 fetal	 calf	 serum	 (FCS)	 was	 purchased	 from	 Biochrome	
KG;	 (Berlin,	 Germany),	 Goat‐anti	 mouse	 IgM	 conjugated	 with	
horseradish	 peroxidase	 and	 Goat‐anti	 mouse	 IgG	 conjugated	
with	 horseradish	 peroxidase	 were	 purchased	 from	 KPL	
(Gaithersburg,	MD,	 USA).	 All	melting	 points	were	 determined	
using	Electrothermal	Capillary	melting	point	apparatus	and	are	
uncorrected.	 Infrared	 (IR)	 spectra	were	 recorded	 as	 thin	 film	
(for	oils)	in	NaCl	discs	or	as	KBr	pellets	(for	solids)	with	JASCO	
FT/IR‐6100	Spectrometer	 and	values	 are	 represented	 in	 cm‐1. 
Mass	 spectral	 data	 were	 obtained	 with	 electron	 impact	 (EI)	
ionization	 technique	 at	 70	 eV	 from	 a	 Finnigan	Mat	 SSQ‐7000	
Spectrophotometer.	 1H	 NMR	 (300	 or	 500	MHz)	 and	 13C	 NMR	
(125	 MHz)	 spectra	 were	 carried	 out	 on	 Jeol	 ECA	 500	 MHz	
spectrometer	 and	 Bruker	 300	 MHz	 using	 TMS	 as	 internal	
standard	and	chemical	shift	values	were	recorded	in	ppm	on	δ	
scale.	The	1H	NMR	data	were	represented	as	follows:	chemical	
shifts,	 multiplicity	 (s.	 singlet,	 d.	 doublet,	 t.	 triplet	 and	 m.	
multiplet),	 number	 of	 protons,	 and	 type	 of	 protons.	 The	 13C	
NMR	 data	 were	 represented	 as	 chemical	 shifts	 and	 type	 of	
carbons.	Silica	gel	TLC	(thin	layer	chromatography)	cards	from	
Merck	 (silica	 gel	 precoated	 aluminum	 cards	 with	 fluorescent	
indicator	at	245	nm)	were	used	for	thin	layer	chromatography.	
Visualization	 was	 performed	 by	 illumination	 with	 UV	 light	
source	(254	nm).		
	
2.2.	Methods	
	
2.2.1.	Chemistry	
	
2.2.1.1.	Synthesis	of	5‐aryl‐1,3,4‐thiadiazol‐2‐amines	(3a‐e)		
	
A	mixture	 of	 substituted	 benzoic	 acid	 (1a‐e)	 (0.033	mol),	
thiosemicarbazide	 (2)	 (0.033	 mol,	 3.0	 g)	 and	 phosphorusoxy	
chloride	 (POCl3)	 (10	mL)	was	 refluxed	gently	 for	30	min.	The	
heating	 was	 stopped	 and	 water	 (100	 mL)	 was	 added	 very	
slowly	 till	 complete	 decomposition	 of	 POCl3	 then	 the	mixture	
was	rendered	alkaline	under	cooling	using	50%	KOH	solution.	
The	 formed	 precipitate	 was	 filtered,	 washed	with	 water,	 and	
dried	 to	 afford	 the	 corresponding	 1,3,4‐thiadiazol‐2‐amines	
(3a‐e)	(Scheme	1).	
5‐Phenyl‐1,3,4‐thiadiazol‐2‐amine	 (3a):	 Yield:	 61%.	 M.p.:	
260	°C	(Lit.	225‐226	°C)	[15].	
5‐(4‐Bromophenyl)‐1,3,4‐thiadiazol‐2‐amine	 (3b):	 Yield:	
47%.	M.p.:	210‐212	°C	(Lit.	222‐224	°C)	[16].	
5‐p‐Tolyl‐1,3,4‐thiadiazol‐2‐amine	 (3c):	 Yield:	 61%.	 M.p.:	
216	°C	(Lit.	214‐216	°C)	[15].	
5‐(4‐Methoxyphenyl)‐1,3,4‐thiadiazol‐2‐amine	 (3d):	 Yield:	
61%.	M.p.:	186	°C	(Lit.	187‐189	°C)	[17].	
5‐Benzyl‐1,3,4‐thiadiazol‐2‐amine	 (3e):	 Yield:	 42%.	 M.p.:	
206	°C	(Lit.	205‐210	°C)	[18].	
	
2.2.1.2.	Synthesis	of	ethyl	5‐aryl‐1,3,4‐thiadiazol‐2‐yl	
carbamates	(4a‐e)	
	
Thiadiazole	 derivatives	 3a‐e	 (0.02	 mol)	 was	 dissolved	 in	
pyridine	 20	 mL	 followed	 by	 addition	 of	 ethylchloroformate	
(0.022	 mol,	 2.13	 g,	 2.0	 mL).	 The	 mixture	 stirred	 at	 room	
temperature	 overnight	 then	 poured	 on	 ice‐cold	 aqueous	 HCl	
(200	mL	20%).	The	precipitate	was	filtered	washed	with	water,	
and	 dried	 to	 afford	 the	 corresponding	 carbamates	 4a‐e	
(Scheme	1).	
Ethyl	 5‐phenyl‐1,3,4‐thiadiazol‐2‐ylcarbamate	 (4a):	 Yield:	
53%.	M.p.:	206‐208	°C	(Lit.	198‐200	°C)	[19].	
Ethyl	 5‐(4‐bromophenyl)‐1,3,4‐thiadiazol‐2‐ylcarbamate	
(4b):	 Yield:	 68%.	 M.p.:	 Decomposition.	 1H	 NMR	 (300	 MHz,	
CDCl3,	δ,	ppm):	0.8	 (m,	3H,	CH2CH3),	3.8	 (m,	2H,	CH2CH3),	7.2‐
7.4	(m,	4H,	Ar‐H).	
Ethyl	 5‐p‐tolyl‐1,3,4‐thiadiazol‐2‐ylcarbamate	 (4c):	 Yield:	
88%.	M.p.:	280	°C.	1H	NMR	(300	MHz,	CDCl3,	δ,	ppm):	0.9	(t,	3H,	
J	 =	 6.9	 Hz,	 CH2CH3),	 2.4	 (s,	 3H	 CH3),	 4.4	 (q,	 2H,	 J	 =	 6.85	 Hz,	
CH2CH3),	7.2	(d,	2H,	J	=	8.5	Hz,	Ar‐H),	7.8	(d,	2H,	J	=	7.6	Hz,	Ar‐
H).	
Ethyl	 5‐(4‐methoxyphenyl)‐1,3,4‐thiadiazol‐2‐ylcarbamate	
(4d):	 Yield:	 86%.	 M.p.:	 206	 °C.	 1H	 NMR	 (300	 MHz,	 CDCl3,	 δ,	
ppm):	0.9	(t,	3H,	J	=	6.85	Hz,	CH2CH3),	3.8	(s,	3H	OCH3),	4.4	(q,	
2H,	J	=	6.9	Hz,	CH2CH3),	7.0	(d,	2H,	J	=	8.4	Hz,	Ar‐H),	7.8	(d,	2H,	J	
=	7.6	Hz,	Ar‐H).	
Ethyl	 5‐benzyl‐1,3,4‐thiadiazol‐2‐ylcarbamate	 (4e):	 Yield:	
36%.	M.p.:	132‐134	°C	(Lit.	138‐140	°C)	[19].	
	
2.2.1.3.	Synthesis	of	N‐(5‐aryl‐1,3,4‐thiadiazol‐2‐yl)	
hydrazinecarboxamides	(5a‐e)	
	
A	 mixture	 of	 the	 appropriate	 carbamate	 4a‐e	 (1	 g)	 and	
hydrazine	hydrate	 (10	mL)	was	stirred	under	reflux	 for	18	hr	
(TLC	controlled).	After	completion	of	the	reaction,	the	mixture	
was	cooled	and	filtered	to	afford	the	corresponding	thiadiazole‐
2‐hydrazinecarboxamides	(5a‐e)	(Scheme	1).	
N‐(5‐Phenyl‐1,3,4‐thiadiazol‐2‐yl)hydrazinecarboxamide	
(5a):	Yield:	50%.	M.p.:	240	°C.	FT‐IR	(KBr,	ν,	cm‐1):	3277	(NH2),	
3083	(NH),	1633	(C=O),	1515	(C=N).	1H	NMR	(500	MHz,	DMSO‐
d6/Methanol‐d4,	δ,	ppm):	7.3‐7.7	(m,	5H,	Ar‐H),	7.72	(s,	2H,	NH).	
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13C	NMR	(125	MHz,	DMSO‐d6,	δ,	ppm):	126	(CH),	129	(CH),	130	
(CH),	131	(C),	156	(C=O),	169	(C=N).	MS	(m/z):	236.00	[M+H]+.	
N‐(5‐(4‐Bromophenyl)‐1,3,4‐thiadiazol‐2‐yl)hydrazine	
carboxamide	(5b):	Yield:	38%.	M.p.:	202	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3277	(NH2),	3074	(NH),	1637	(C=O),	1511	(C=N).	1H	NMR	(500	
MHz,	DMSO‐d6/Methanol‐d4,	δ,	ppm):	7.5‐7.7	(m,	4H,	Ar‐H).	13C	
NMR	 (125	MHz,	 DMSO‐d6,	 δ,	 ppm):	 123	 (CH),	 128	 (CH),	 130	
(CH),	132	(C),	157	(C=O),	169	(C=N).	MS	(m/z):	314.00	[M+H]+	
N‐(5‐(4‐Methylphenyl)‐1,3,4‐thiadiazol‐2‐yl)hydrazine	
carboxamide	(5c):	Yield:	27%.	M.p.:	160	°C.	FT‐IR	(KBr,	ν,	cm‐1):	
3285	(NH2),	3085	(NH),	1636	(C=O),	1513	(C=N).	1H	NMR	(500	
MHz,	 DMSO‐d6/Methanol‐d4,	 δ,	 ppm):	 2.3	 (s,	 3H,	 CH3),	 7.2‐7.6	
(m,	 4H,	 Ar‐H).	 13C	 NMR	 (125	 MHz,	 DMSO‐d6,	 δ,	 ppm):	 21.4	
(CH3),	 126.7	 (CH),	 128.8	 (CH),	 130	 (CH),	 139	 (C),	 157	 (C=O),	
168	(C=N).	MS	(m/z):	248.00	[M‐H]+.		
N‐(5‐(4‐Methoxyphenyl)‐1,3,4‐thiadiazol‐2‐yl)hydrazine	
carboxamide	(5d):	Yield:	37%.	M.p.:	198‐200	°C.	FT‐IR	(KBr,	ν,	
cm‐1):	 3273	 (NH2),	 3098	 (NH),	 1608	 (C=O),	 1514	 (C=N).	 	 1H	
NMR	 (500	 MHz,	 DMSO‐d6/Methanol‐d4,	 δ,	 ppm):	 3.8	 (s,	 3H,	
CH3),	 7.0‐7.7	 (m,	 4H,	 Ar‐H).	 13C	 NMR	 (125	 MHz,	 DMSO‐d6,	 δ,	
ppm):	55.8	 (CH3),	115	(CH),	124	(CH),	128	(CH),	156	(C),	160	
(C=O),	168	(C=N).	MS	(m/z):	265.00	[M]+.	
N‐(5‐Benzyl‐1,3,4‐thiadiazol‐2‐yl)hydrazinecarboxamide	
(5e):	 Yield:	 43%.	M.p.:	 204‐206	 °C.	 FT‐IR	 (KBr,	 ν,	 cm‐1):	 3444	
(NH2),	3163	(NH),	1728	(C=O),	1564	(C=N).	1H	NMR	(500	MHz,	
DMSO‐d6/Methanol‐d4,	δ,	ppm):	4.2	(s,	2H,	CH2),	7.0‐7.2	(m,	5H,	
Ar‐H).	 13C	NMR	(125	MHz,	DMSO‐d6,	 δ,	ppm):	39.7	 (CH2),	127	
(CH),	129	(CH),	138	(CH),	138.5	(C),	158	(C=O),	169	(C=N).	MS	
(m/z):	249.10	[M]+.	
	
2.2.2.	Biology	
	
2.2.2.1.	Anticonvulsant	screening	tests	
	
2.2.2.1.1.	Subcutaneous	pentylenetetrazole	test	
	
To	 determine	 the	 production	 of	 threshold	 or	 minimal	
(clonic)	seizures,	scPTZ	test	was	performed,	where	an	aqueous	
solution	of	PTZ	at	 a	 dose	 of	85	mg/kg	 [20]	was	 administered	
subcutaneously	 in	a	 loose	 fold	of	skin	on	the	back	of	 the	mice	
neck.	 Six	 mice	 were	 used	 in	 both	 the	 control	 and	 the	
experimental	 groups.	 The	 test	 is	 carried	 out	 by	 injecting	 PTZ	
subcutaneously	 30	 minutes	 after	 i.p.	 injection	 of	 the	 test	
compounds	 at	 dose	 level	 of	 100	 mg/kg.	 The	 animals	 were	
observed	 for	 the	 following	 30	 minutes	 for	 the	 occurrence	 of	
seizures.	A	threshold	convulsion	was	defined	as	one	episode	of	
clonic	 convulsions	 which	 persist	 for	 at	 least	 a	 5	 s	 period.	
Absence	 of	 a	 single	 5	 s	 episode	 of	 clonic	 spasms	 during	 the	
period	 of	 observation	 is	 taken	 as	 the	 end	 point	 in	 this	 test	
[21,22].	
	
2.2.2.1.2.	Maximal	electroshock	seizure	test	
	
Half	an	hour	after	 i.p.	 injection	of	 the	test	compound	(100	
mg/kg),	electroconvulsions	were	produced,	by	a	current	(fixed	
current	 intensity	 of	 25mA,	 0.2	 s	 stimulus	 duration)	 delivered	
via	 ear‐clip	 electrodes	 by	 a	 Rodent	 Shocker	 generator	
(constant‐current	stimulator	Type	221,	Hugo	Sachs	Elektronik,	
Freiburg,	 Germany).	 Six	mice	were	 used	 in	 the	 control	 group	
and	 in	 the	 experimental	 groups.	 The	 criterion	 for	 the	
occurrence	of	seizure	activity	was	the	tonic	hind	limb	extension	
(i.e.,	the	hind	limbs	of	animals	outstretched	120	°C	to	the	plane	
of	the	body	axis)	[23].	
	
2.2.2.1.3.	Neurotoxicity	screen	
	
The	neurotoxicity	of	the	animals	was	evaluated	by	adopting	
rotarod	 test	 [24].	 In	 this	 test,	 the	 animals	 were	 trained	 to	
maintain	 equilibrium	 on	 a	 rotating	 1	 in.	 diameter	 knurled	
plastic	 rod	 (rotarod,	 UGO	 Basile,	 47600,	 Varese,	 Italy)	 at	 a	
speed	 of	 10	 rpm	 for	 60	 seconds	 (sec)	 in	 each	 of	 three	 trials.	
Only	 animals	 that	 fulfill	 this	 criterion	 were	 included	 into	 the	
experiment.	 The	 animals	 in	 the	 experimental	 groups	 (n	 =	 6)	
were	given	an	i.p.	 injection	of	one	of	the	test	compounds	(100	
mg/kg	in	7%	aqueous	suspension	of	tween‐80).	Thirty	minutes	
later,	 the	mice	were	placed	 again	 on	 the	 rotating	 rod	 and	 the	
motor	 performance	 time	 was	 recorded	 up	 to	 60	 sec.	 The	
neurotoxicity	 was	 indicated	 by	 the	 inability	 of	 the	 animal	 to	
maintain	equilibrium	on	the	rod	for	at	least	60	sec.		
		
2.2.2.2.	Immunomodulatory	activity	
	
2.2.2.2.1.	Detection	of	humoral	and	cellular	immune	
responses	
	
Compounds	 were	 suspended	 in	 1%	 tween‐80	 aqueous	
solutions.	Mice	were	divided	into	seven	groups	(5mice/group).	
The	1st,	2nd,	 3rd,	4th	 and	5th	groups	were	 injected	with	a	single	
dose	(100	mg/kg)	of	the	test	compounds	5a,	5b,	5c,	5d,	and	5e,	
respectively.	Meanwhile,	the	6th	group	received	the	vehicle	(1%	
tween‐80	in	aqueous	solution)	and	served	as	vehicle	group.	The	
7th	group	was	injected	with	phosphate	buffer	saline	(PBS)	and	
was	used	as	normal	for	the	cellular	immune	response	detection	
from	MLN	and	liver	histopathological	examination.	
Blood	 samples	 were	 collected	 at	 intervals,	 0	 and	 30	
minutes,	2	hours,	1	day,	1,	2,	3	and	4	weeks	post	injection	from	
individual	mice.	 The	 sera	were	 separated	by	 centrifugation	 at	
14,000	g	at	4	°C	for	20	min,	and	then	frozen	at	‐20	°C	till	being	
used.	
	
2.2.2.2.2.	Detection	of	IgM	and	IgG	levels	using	enzyme	
linked	immunosorbent	assay	(ELISA)	
	
The	 IgM	 and	 IgG	 sera	 levels	 in	 different	 experimental	
groups	 were	 detected	 by	 ELISA	 according	 to	 Maghraby	 and	
Bahgat	 (2004)	 [25]	 on	 plates	 coated	 with	 50	 µL/well	 sera	
(1:100).	After	coating,	plates	were	incubated	overnight	at	4	°C,	
washed	 three	 times	 with	 PBS	 containing	 0.05%	 Tween‐20	
(PBS‐T).	Plates	were	blocked	against	non‐specific	binding	using	
100µl/well	 of	 blocking	 buffer	 [PBS‐T	 in	 5%	 fetal	 calf	 serum	
(FCS)]	and	incubated	at	37	°C	for	2	h.	After	three	washes	with	
PBS‐T,	 peroxidase	 conjugated	 anti‐mouse	 IgM	 and	 IgG	 were	
added	50	µL/well	at	dilution	(1:500	for	IgG	and	1:1000	for	IgM)	
in	 (PBS‐T‐FCS)	 to	 detect	 total	 IgM	 and	 IgG	 levels.	 Then	 the	
plates	were	 incubated	at	37	 °C	 for	1	hr	 followed	by	3	washes	
with	 PBS‐T.	 A	 volume	 of	 50	 μL/well	 of	 o‐phenylenediamine	
(OPD)	 substrate	 diluted	 in	 substrate	 buffer	was	 used	 and	 the	
plates	 were	 left	 for	 10	 min	 at	 room	 temperature	 till	 color	
development.	The	enzymatic	reaction	was	stopped	using	20	µL	
of	2	M	 sulphuric	 acid	 and	 the	 changes	 in	optical	density	 (OD)	
were	recorded	at	λ	max	490	nm	using	a	multi‐well	plate	reader	
(Tecan;	Sunrise,	Austria,	GmbH).	
	
2.2.2.2.3.	Counting	the	total	mesenteric	lymph	nodes	
lymphocytes	
	
Animals	 were	 sacrificed	 at	 four	 weeks	 post‐injection;	
mesenteric	lymph	nodes	(MLNs)	were	excised,	gently	teased	in	
Petri	dishes	containing	PBS‐T‐FCS	using	glass	slides.	Cells	were	
washed	three	times	with	PBS‐T‐FCS	by	centrifugation	at	1500	g	
at	 4	 °C	 for	 10	 min.	 An	 estimate	 of	 cell	 number	 in	 MLN	 was	
obtained	 using	 haemocytometer.	 An	 aliquot	 cell	 suspension	
was	 diluted	 1:1	 in	 4%	 trypan	 blue.	 The	 total	 number	 of	
lymphocytes	 was	 determined	 using	 light	 microscope	 (Zeiss	
Axioskop,	Jena,	Germany)	[26].	
	
2.2.2.2.4.	Histopathological	examination	
	
Slides	 with	 the	 dry	 paraffin	 liver	 sections	 from	 each	
individual	mouse	were	immersed	in	2	×	5	min	baths	of	xylol	at	
room	 temperature.	 Xylol	was	 removed	 by	 2	 ×	 5	min	 baths	 of	
79%	 ethanol,	 rinsed	 in	 tap	 water	 and	 stained	 by	 the	 routine	
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method	[26].	The	slides	were	dipped	in	haematoxylin	for	10‐15	
min,	washed	 for	5	min	 in	 tap	water	 to	eliminate	 the	excess	of	
haematoxylin	and	cleaned	with	filter	paper	around	the	section,	
then	 counter	 stained	 with	 eosin	 for	 5‐10	 min,	 rinsed	 in	 tap	
water	and	dehydrated	in	2	×	2	min	baths	of	79%	ethanol.	The	
slides	were	cleared	in	2	×	2	min	baths	of	xylol	which	is	miscible	
with	 both	 alcohol	 and	 mounting	 agent.	 The	 stained	 sections	
were	 mounted	 with	 Canada	 balsam	 and	 examined	 under	 the	
light	microscope	at	fixed	magnification.	
	
2.2.2.2.5.	Statistical	analysis	
	
Results	 were	 expressed	 as	 means±standard	 error	 of	 the	
mean	 (s.e.m).	 Statistical	 analysis	 of	 the	 obtained	 data	 was	
performed	 using	 one‐way	 analysis	 of	 variance	 (ANOVA)	
followed	by	 a	 Student‐Newman‐Keuls	post	 hoc	 comparison.	A	
result	was	considered	statistically	significant	where	p	<	0.05.	
	
3.	Results	and	discussion		
	
3.1.	Chemistry	
	
Scheme	 1	 was	 followed	 in	 order	 to	 synthesize	 the	 target	
compounds	5a‐e	 and	 their	 intermediates	3a‐e	 and	4a‐e.	 The	
synthesis	of	2‐amino‐1,3,4‐thiadiazole	intermediates	(3a‐e)	is	a	
one	 pot	 two‐step	 reaction.	 The	 first	 step	 involves	 the	
condensation	of	 carboxylic	 acids	 (1a‐e)	with	 the	basic	NH2	of	
thiosemicarbazide	(2)	in	the	presence	of	a	coupling	reagent	to	
afford	 the	 thiocarboxamide	 acylhydrazide	 (RCONHNHCSNH2).	
In	the	second	step	the	heterocycle	is	formed	by	intramolecular	
cyclodehydration.	Several	conditions	of	cyclodehydration	have	
been	 reported	 [27],	 for	 instance,	 heating	 in	 solvents	 such	 as	
pyridine,	DMF,	or	in	the	presence	of	additives	such	as	1‐ethyl‐3‐
(3‐dimethylaminopropyl)carbodiimide	 (EDC),	 while	 SOCl2,	
P2O5,	 H2SO4,	 POCl3,	 Burgess	 reagent,	 triphenylphospine,	 and	
triflic	 anhydride	 are	 used	 for	 the	 cyclization.	 In	 the	 present	
work,	 POCl3	 acted	 as	 solvent	 and	 as	 coupling,	 and	 cyclo‐
dehydrating	agent	for	the	synthesis	of	aminothiadiazoles	3a‐e.	
Removal	 of	 POCl3	 by	 addition	 of	 water	 (very	 carefully	 and	
slowly)	 without	 cooling	 was	 crucial	 step	 in	 order	 to	 obtain	
filterable	powder	after	basification	with	KOH.		
Achievement	 of	 target	 compounds	 5a‐e	 from	 2‐amino‐5‐
aryl‐1,3,4‐thiadiazoles	 (3a‐e)	 could	 be	 reached	 via	 different	
pathways	such	as	conversion	of	amines	3a‐e	to	urea,	by	Wöhler	
synthesis,	 or	 to	 carbamates.	 Then	 the	 urea	 or	 carbamate	 is	
reacted	 with	 hydrazine	 hydrate	 to	 afford	 the	 target	 products	
5a‐e.	 In	 the	 present	 study,	 converting	3a‐e	 to	 urea	was	 tried	
but	 annoying	 troubles	 have	 been	 faced	 due	 to	 the	 very	 low	
solubility	of	compounds	3a‐e	even	 in	acetic	acid	with	heating.	
Thus	we	preferred	to	shift	towards	the	carbamate	synthesis.	
Carbamates	 have	 been	 accomplished	 by	 several	 methods	
including	carbonization	of	amines	or	imines	by	chloroformate,	
[28,29]	 or	 oximinoacetoacetate	 [30],	 organic	 acids	 in	 the	
presence	 of	 azides	 [31,32],	 organic	 carbonate	 under	 solvent‐
free	 conditions	 [33,34]	 and/or	 metal‐mediated	 reductive	
acylation	 of	 nitriles	 [35]	 or	 oxime	 carbonates	 [36].	 In	 the	
present	 work,	 reaction	 of	 the	 appropriate	 amine	 with	 ethyl	
chloroformate	 in	 different	 solvents	 (chloroform,	 THF,	 and	
DMF)	 at	 room	 temperature	 and	 higher	 temperatures	 in	
presence	 of	 amine	 (triethylamine)	 was	 tried	 but	 the	 low	
solubility	 of	 compounds	 3a‐e	 prevented	 the	 reactions	 from	
going	forward.	Finally,	it	has	been	decided	to	use	the	powerful	
solvent	and	base	pyridine	as	reaction	medium	where	all	amines	
3a‐e	were	soluble	at	room	temperature	or	with	slight	warming.	
Stopping	 the	 reaction	 by	 pouring	 on	 aqueous	 HCl	 solution	
afforded	 the	 target	 carbamates	4a‐e	 in	good	yields.	The	 faced	
troubles	during	 the	 reaction	of	amines	3a‐e	with	 cyanate	 (for	
urea	 synthesis)	 or	 chloroformate	 (for	 carbamate	 synthesis)	
could	also	be	retrieved	to	the	weak	basic	properties	of	2‐NH2	as	
a	 result	 of	 the	 negative	mesomeric	 and/or	 inductive	 effect	 of	
the	1,3,4‐thiadiazole	ring.	
Hydrazinecarboxamides	 5a‐e	 were	 obtained	 by	 refluxing	
carbamates	4a‐e	with	hydrazine	hydrate.	The	structure	of	 the	
final	 compounds	 5a‐e	 was	 confirmed	 by	 spectral	 (FT‐IR,	 1H	
NMR	and	MS)	analyses.	 In	 the	 IR	spectra	bands	at	3370‐3450	
and	 3070‐3170	 cm‐1	 have	 been	 observed	 for	 NH2	 and	 amidic	
NH	while	 imine	 and	 carbonyl	 bands	have	 been	 seen	 at	 1600‐
1640	 and	 1510‐1520	 cm‐1,	 respectively.	 In	 the	 1H	 NMR,	 the	
aromatic	 protons	 have	 been	 observed	 at	 7.0‐8.0	 ppm	 but	 the	
analyses	 were	 performed	 in	 DMSO‐d6/Methanol‐d4	 thus	 the	
exchangeable	 amidic	 NH	 were	 absent	 except	 of	 5a.	 For	 13C	
NMR,	all	carbons	have	been	assigned	particularly	the	carbonyl	
and	imine	carbons	at	150‐160	and	160‐170	ppm,	respectively.	
	
3.2.	Biology	
	
3.2.1.	Anticonvulsant	
	
The	 use	 of	 predictable	 animal	 models	 is	 essential	 for	 the	
discovery	 of	 new	 bioactive	 chemical	 candidates	 for	 the	
treatment	of	epilepsy.	The	antiepileptic	drugs	(AEDs)	discovery	
programs,	 allotted	 three	 in‐vivo	 animal	 models	 including	
subcutaneous	 pentylenetetrazole	 (scPTZ),	 maximal	 electro‐
shock	 seizures	 (MES),	 and	 the	 kindling	 model.	 From	 these	
animal	 models,	 the	 scPTZ	 and	 MES	 seizure	 models,	 are	
extensively	 used	 are	 the	 search	 for	 novel	 AEDs	 as	 they	 are	
considered	as	the	“gold	standards”	in	the	early	stages	of	testing	
[37].	Interestingly,	these	two	test	systems	have	been	claimed	to	
detect	 new	bioactive	 chemical	 entities	 affording	 protection	 to	
generalized	 absence	 (“petit	 mal”)	 seizures	 and	 generalized	
tonic‐clonic	(“grand	mal”)	seizures,	respectively	[22].	
The	 initial	 anticonvulsant	 activity	 (Phase	 1	 screening)	 of	
newly	synthesized	compounds	were	evaluated	according	to	the	
protocol	 given	 by	 the	 epilepsy	 section	 of	National	 Institute	 of	
Neurological	Disorders	and	Stroke	(NINIDS)	using	the	standard	
protocol	adopted	by	the	Antiepileptic	Drug	Development	(ADD)	
program	 [38].	 Those	 include	 the	 subcutaneous	 pentylene	
tetrazole	(scPTZ)	screen,	which	is	used	to	 identify	compounds	
that	 elevate	 seizure	 threshold,	 and	 maximal	 electroshock	
seizure	 (MES)	 screen,	which	 is	 indicative	 of	 the	 ability	 of	 the	
test	compounds	to	prevent	seizure	spread.	
The	 obtained	 data,	 expressed	 as	 %	 protection	 for	 the	
anticonvulsant	 activity	 of	 the	 test	 compounds	5a‐e	 as	well	 as	
their	neurotoxicity	are	presented	in	Table	1	and	2.	
The	 initial	 anticonvulsant	 evaluation	 indicated	 that	 all	 the	
tested	compounds	were	effective	in	i.p.	MES	and	scPTZ	screens.	
In	the	MES	test,	all	of	the	new	entities	showed	protection	in	83	
and	 100%	 at	 the	 tested	 dose	 level	 of	 100	mg/kg	 after	 0.5	 hr	
from	 compound	 administration,	 indicating	 their	 ability	 to	
protect	mice	 from	 seizure	 spread.	 Compounds	5b	 and	5e	 are	
the	most	potent	congeners	as	 they	exhibited	100%	protection	
against	 maximal	 electric	 shock	 at	 dose	 level	 of	 100	 mg/kg.	
Moreover,	 compounds	5a,	5c	 and	5d,	 at	 the	 same	 dose	 level	
exerted	 equipotent	 activity	 of	 83%	 protection.	 Meanwhile	
diphenyl	 hydantoin,	 used	 as	 reference	 drug,	 exhibit	 100%	
protection	at	dose	level	of	40mg/kg.	
Concerning	 the	 scPTZ	 screen,	 compound	5e	 (100	mg/kg)	
was	 found	 to	 be	 the	 most	 potent	 as	 it	 exhibited	 100%	
protection	against	scPTZ‐induced	seizures	in	mice.	Meanwhile,	
the	reference	drug	exhibited	100%	protection	at	dose	 level	of	
40	 mg/kg.	 On	 the	 other	 hand,	 compound	 5a,	 5b,	 5c	 and	 5d	
exhibited	 equipotent	 activity	 of	 50%	 protection	 at	 the	 tested	
dose	level	(100	mg/kg).	
Regarding	 the	 neurotoxicity,	 acute	 toxicity	 from	
antiepileptic	 drugs	 in	 rodents	 almost	 invariable	 is	manifested	
by	neurological	deficits.	These	 include	sedation,	altered	motor	
activity,	ataxia,	and	impaired	righting	reflexes.	These	effects	of	
antiepileptic	 drugs	 are	 often	 summarized	 by	 tern	
“neurotoxicity”.	Minimal	neurological	deficit,	 such	as	 impaired	
motor	 function,	can	be	detected	by	standardized	 test	 (rotarod	
test)	[24].	
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Table	1.	Anticonvulsant	activity	of	compounds	5a‐e	against	pentylenetetrazole	and	electro‐induced	seizures	in	mice.	
Anticonvulsant	activity	(%	protection)	Dose,	mmol/kg	(mg/kg)	Compound	number	
Sc	PTZ	bMES	a
0	0	0	Control	
100	100	0.159	(40)	Diphenyl	hydantoin	
5083.30.425	(100)		5a	
501000.318	(100)	5b	
5083.30.400	(100)	5c	
5083.30.377	(100)	5d	
1001000.318	(100)	5e	
a	Data	show	the	percentage	protection	of	MES‐induced	seizures	in	mice.	Animals	(n	=	6)	were	injection	i.p.	with	the	test	compound	(100	mg/kg).	30	min	latter	the	
mice	were	subjected	to	electroconvulsions	by	a	current	(fixed	current	intensity	of	25	mA,	0.2	s	stimulus	duration)	delivered	via	ear‐clip	electrodes	by	a	Rodent	
Shocker	generator.	
b	Data	show	the	percentage	protection	of	scPTZ‐induced	seizures	in	mice.	Animals	(n	=	6)	were	sc.	injected	with	PTZ	(85	mg/kg),	30	min	after	intraperitoneal	
injection	of	the	test	compounds.	The	mice	were	observed	during	the	30	min	post	injection	of	scPTZ	for	the	occurrence	of	seizures.	
	
	
Table	2.	Neurotoxicity	screen	of	compounds	5a‐e	by	adopting	rotarod	test.	
%	of	animals	devoided	of	neurotoxicityNumber	of	animals	falling	the	rotating	rodDose	mmol/kg	(mg/kg)	Compound	number	
33.3	4/6	0.425	(100)		5a	
100	0/6	0.318	(100)	5b	
100	0/6	0.400	(100)	5c	
66.72/60.377	(100)	5d	
1000/60.318	(100)	5e	
	
	
The	 results	 of	 the	 neurotoxicity	 screening	 test	 (Table	 2)	
revealed	 that,	 compounds	 5b,	 5c	 and	 5e	 were	 devoid	 from	
neurotoxicity,	 meanwhile	 compounds	 5a	 and	 5d	 exhibited	
moderate	neurotoxicity	at	a	dose	of	100	mg/kg.		
From	the	present	results	we	can	deduce	that	compound	5e	
was	 the	most	 potent	 congener	 as	 it	 showed	 100%	protection	
against	 both	MES	 as	well	 as	 scPTZ‐induced	 seizures	 and	was	
devoid	 of	 neurotoxicity	 Meanwhile,	 compound	 5b	 demonst‐
rated	100%	protection	against	MES‐induced	seizures	only	and	
did	not	exhibit	any	neurotoxic	effect.	
Groups	of	animals	 (n	=	6)	were	examined	30	min	after	 i.p	
administration	 of	 one	 of	 the	 tested	 compounds	 5a‐e	 (100	
mg/kg).	Thirty	minutes	later	mice	were	placed	on	the	rotating	
rod	 and	 the	motor	 performance	 time	was	 recorded	 up	 to	 60	
sec.	
	
3.2.2.	Humoral	immune	responses	
	
3.2.2.1.	Detection	of	IgM	levels	in	sera	from	mice	injected	
with	compounds	5a‐e	
	
Sera	IgM	levels	at	30	minutes	post	injection	of	compounds	
5a	 and	5d	 or	 vehicle	 exhibited	 significant	 increase	 compared	
with	normal,	compound	5b,	5c	or	5e,	respectively.	On	the	other	
hand,	 IgM	 levels	 in	 sera	of	mice	 injected	with	 compounds	5b,	
5c	 and	 5e	 showed	 no	 significant	 change	 compared	 to	 the	
normal	 IgM	 level.	 Moreover,	 compounds	 5a	 and	 5d	 exerted	
increase	 in	 IgM	levels	by	1.16	and	1.14‐folds	compared	 to	 the	
vehicle	level,	respectively	(Figure	4).	At	2	hours	post	injection,	
sera	IgM	level	of	compound	5a	and	5d	or	vehicle	demonstrated	
significantly	 higher	 value	 than	 the	normal	 one	or	 that	 of	 sera	
IgM	 of	 mice	 injected	 with	 compound	 5b,	 5c	 or	 5e.	 The	 IgM	
levels	 in	sera	from	mice	 injected	with	compound	5b,	5c	or	5e	
were	significantly	 lower	than	the	vehicle	 level	and	showed	no	
significant	 difference	 from	 the	 normal	 level.	 In	 addition,	
compounds	 5a	 and	 5d	 demonstrated	 1.25	 and	 1.22‐folds	
increase	 in	 IgM	 level	 compared	 to	 vehicle	 IgM	 serum	 level,	
respectively.	
Sera	from	mice	injected	with	compound	5a	or	5d	for	1	day	
showed	1.52	and	1.46‐folds	 increase	 in	IgM	level	compared	to	
the	 normal	 value,	 respectively.	 Similarly,	 the	 IgM	 level	 of	
compound	 5a	 or	 5d	 showed	 1.15	 and	 1.11‐folds	 increase	
compared	 to	 vehicle	 IgM	 serum	 level.	 Compounds	5b,	5c	and	
5e	exhibited	0.69,	0.56	and	0.67‐folds	compared	to	the	vehicle.	
At	 1	week	 post	 injection	 of	 compound	5a	 or	5d,	 the	 IgM	
levels	were	significantly	higher	compared	to	the	normal	values,	
compound	 5b,	 5c	 or	 5e	 IgM	 sera	 level.	 Moreover,	 the	 mice	
injected	with	compound	5b,	5c	or	5e,	 their	IgM	levels	showed	
0.63,	 0.67	 and	 0.8‐folds	 compared	 to	 the	 vehicle	 levels,	
respectively.	Interestingly,	sera	IgM	levels	of	mice	injected	with	
compound	 5a	 was	 significantly	 higher	 than	 that	 of	 mice	
injected	with	the	vehicle.	 IgM	sera	 levels	of	mice	injected	with	
compound	5d	 demonstrated	 1.27‐folds	 increase	 compared	 to	
that	of	vehicle.	
	
	
	
Figure	4. Determination	of	 the	IgM	level	 in	sera	 from	normal,	vehicle,	mice	
injected	with	single	dose	(100	mg/kg)	of	test	compounds	5a,	5b,	5c,	5d	and	
5e.	IgM	normal	levels	were	detected	at	zero‐time	before	the	injection	of	the	
test	compounds	or	the	Vehicle.	Blood	samples	were	collected	at	intervals,	30	
minutes,	 2	hours,	 1	day,	1,	 2,	 3	 and	4	weeks	post	 injection	 from	 individual	
mice	for	the	determination	of	IgM	sera	level.	Data	presented	as	mean±SEM	(n	
=	5).	$	Significantly	different	 from	normal	group	at	p	<	0.05.	 *	Significantly	
different	from	vehicle	at	p	<	0.05,	a	significantly	different	from	compound	5a	
at	 p	 <	 0.05,	 b	 significantly	 different	 from	 compound	 5b	 at	 p	 <	 0.05,	 c	
significantly	different	from	compound	5c	at	p	<	0.05,	d	significantly	different	
from	compound	5d	at	p	<	0.05,	e	significantly	different	from	compound	5e	at	
p	<	0.05.	
	
	
At	2	weeks,	the	IgM	response	in	the	mice	sera	injected	with	
compound	 5a	 and	 5d	 or	 the	 vehicle	 was	 significantly	 higher	
than	 the	 normal	 values,	 as	 well	 as	 from	 mice	 injected	 with	
compound	 5b,	 5c	 or	 5e.	 Additionally,	 IgM	 sera	 levels	 of	
compound	 5b,	 5c	 or	 5e	 were	 0.55,	 0.54,	 and	 0.66‐folds,	
respectively	compared	to	the	normal	level.	Also,	sera	IgM	level	
of	 mice	 injected	 with	 compound	 5a	 was	 significantly	 higher	
than	 that	 of	 vehicle,	 while	 the	 sera	 of	 mice	 injected	 with	
compound	 5d	 demonstrated	 1.12‐fold	 increase	 compared	 to	
the	vehicle	IgM	sera	levels.	
The	IgM	level	 in	 the	sera	collected	 from	mice	three	weeks	
post	 injection	 of	 compound	 5a	 and	 5d	 or	 vehicle	 showed	 a	
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significant	increase	when	compared	with	the	IgM	levels	in	sera	
from	normal,	 compound	5b,	5c	or	5e	 at	 the	 same	 time	point.	
Moreover,	mice	 injected	with	compound	5b,	5c	or	5e	 showed	
no	 significant	 changes	 compared	 to	 the	 normal	 IgM	 level.	
Moreover,	mice	 injected	with	 compound	5a	 showed	1.19‐fold	
increase	in	IgM	level	as	compared	with	the	vehicle	(Figure	4).	
Four	weeks	post	injection	of	the	compounds	5a	and	5d	or	
the	 vehicle,	 the	 response	 of	 the	 IgM	 levels	 was	 significantly	
higher	 than	 that	 of	 the	 normal	 values.	 Interestingly,	 the	 sera	
IgM	levels	of	compounds	5a	and	5d	demonstrated	significantly	
higher	 IgM	 sera	 levels	 than	mice	 injected	with	 compound	5b.	
Moreover,	compound	5b,	5c	or	5e	showed	significant	decrease	
compared	to	the	vehicle	IgM	level.	
	
3.2.2.2.	Detection	of	IgG	levels	in	sera	from	mice	injected	
with	compounds	5a‐e	
	
At	30	minutes	post	injection	of	compound	5a	and	5d	or	the	
vehicle,	 the	 levels	 of	 IgG	 in	 sera	 showed	 significant	 increase	
compared	 with	 the	 normal	 level	 or	 from	 mice	 injected	 with	
compound	 5b,	 5c	 or	 5e.	 Moreover,	 mice	 injected	 with	
compound	5b,	5c	or	5e	 showed	no	significant	 change	compa‐
red	to	the	normal	IgG	level.	In	addition,	both	mice	injected	with	
compound	5a	 and	5d	 showed	1.14	 and	1.22‐folds	 increase	 in	
the	IgG	level	compared	to	vehicle	(Figure	5).	
	
	
Figure	5.	Determination	of	the	IgG	level	in	sera	of	normal,	vehicle	and	mice	
injected	with	single	dose	(100	mg/kg)	of	test	compounds	5a,	5b,	5c,	5d	and	
5e.	 IgG	normal	 levels	were	detected	at	zero‐time	before	the	 injection	of	 the	
test	compounds	or	the	Vehicle.	Blood	samples	were	collected	at	intervals,	30	
minutes,	2	hours,	 1	day,	1,	 2,	3	 and	4	weeks	post	 injection	 from	 individual	
mice	for	the	determination	of	IgG	sera	level.	Data	presented	as	mean	±	SEM	
(n	=	5).	$	Significantly	different	from	normal	group	at	p	<	0.05.	*	Significantly	
different	from	vehicle	at	p	<	0.05,	a	significantly	different	from	compound	5a	
at	 p	 <	 0.05,	 b	 significantly	 different	 from	 compound	 5b	 at	 p	 <	 0.05,	 c	
significantly	different	from	compound	5c	at	p	<	0.05,	d	significantly	different	
from	compound	5d	at	p	<	0.05,	e	significantly	different	from	compound	5e	at	
p	<	0.05.	
	
	
The	IgG	level	in	the	sera	collected	at	2	hours	post	injection	
of	mice	with	compound	5a	or	5d	were	significantly	higher	than	
the	normal,	 compound	5b,	5c	or	5e	 IgG	 level.	Vehicle	showed	
significant	increase	in	sera	IgG	levels	compared	to	the	IgG	level	
in	 the	 sera	 from	 compound	 5b	 or	 5c.	 On	 the	 other	 hand,	
compounds	 5a	 and	 5d	 demonstrated	 1.32	 and	 1.38‐folds	
increase	 in	 IgG	 levels	 compared	 to	 the	 vehicle	 level,	
respectively	(Figure	5).	
At	1	day	post	injection,	the	IgG	levels	in	the	sera	of	the	mice	
injected	with	compounds	5a	and	5d,	demonstrated	a	significant	
increase	compared	to	 the	normal	values	or	compounds	5b,	5c	
and	5e.	Vehicle	showed	significant	increase	in	serum	IgG	levels	
compared	 to	 normal	 levels	 from	 un‐treated	 mice	 and	 those	
injected	with	compounds	5b,	5c	or	5e.	Furthermore,	compound	
5a	and	5d	showed	1.1‐fold	and	1.18‐folds	increase	in	IgG	level	
compared	to	the	vehicle	IgG	level,	respectively	(Figure	5).	
At	 one	 week,	 the	 IgG	 level	 in	 mice	 sera	 injected	 with	
compounds	5a	and	5d	was	significantly	higher	than	that	of	the	
normal,	vehicle,	compounds	5b,	5c,	and	5e	(Figure	5).	
At	 two	weeks	 post	 injection,	 the	 IgG	 serum	 level	 of	 mice	
injected	with	compound	5d	was	found	to	be	significantly	higher	
than	 the	 normal	 or	 compounds	 5b,	 5c	 or	 5e.	 There	 was	 no	
significant	difference	between	the	remaining	groups.	However,	
compound	5d	 demonstrated	1.27‐fold	 increase	 in	 IgG	 level	 as	
compared	to	the	vehicle	level	(Figure	5).	
At	 three	 weeks,	 the	 IgG	 levels	 in	mice	 sera	 injected	with	
compound	5a	 or	5d	was	significantly	higher	 than	 the	normal,	
compounds	5b,	5c	 and	5e	 levels.	 Moreover,	 the	 IgG	 levels	 in	
sera	of	mice	injected	with	compounds	5a	and	5d	demonstrated	
1.17	and	1.33‐	folds	increase	compared	to	vehicle,	respectively	
(Figure	 5).	 There	 is	 no	 significant	 difference	 between	 the	 IgG	
level	of	the	vehicle	and	normal	group.	
At	 four	weeks	post	 injection,	 the	IgG	levels	of	mice	sera	of	
vehicle	 or	 compound	 5d,	 were	 significantly	 higher	 than	 the	
normal	 level.	 Moreover,	 the	 sera	 of	 mice	 injected	 with	
compound	 5d	 demonstrated	 significantly	 higher	 IgG	 levels	
compared	to	sera	from	mice	injected	with	compound	5b	or	5c.	
There	were	no	statistical	changes	in	the	IgG	levels	between	the	
vehicle	group	and	any	of	the	tested	groups	(Figure	5).	
	
3.2.2.3.	Cellular	immune	responses	
	
Data	 of	 the	 cellular	 immune	 responses	 revealed	 that	 the	
mean	of	the	total	number	of	MLN	cells	from	mice	injected	with	
5a	 (114.9±37),	 5b	 (128.5±13.8),	 5c	 (121.5±	 54.4),	 5d	
(95.6±29.3),	and	5e	(124	±24.4)	showed	insignificant	increase	
(1.30,	1.45,	1.38,	1.08	and	1.41‐folds,	respectively)	as	compared	
with	 total	 number	 of	 normal	MLN	 cells	 (88.1±18)	 (Figure	 6).	
There	 was	 an	 insignificant	 decrease	 in	 the	 mean	 of	 total	
number	 of	 MLN	 cells	 of	 the	 vehicle	 (66.6±18.6)	 as	 compared	
with	 that	 of	 the	normal	 or	mice	 injected	with	 compounds	5d,	
5a,	5c	or	5e	(0.76,	0.7,	0.58,	0.55	and	0.54,	folds,	respectively).	
Meanwhile,	 there	 was	 a	 1.92‐fold	 increase	 in	 mean	 total	
number	of	MLN	cells	of	mice	injected	with	compound	5b	or	the	
vehicle.	On	the	other	hand,	no	significant	change	in	the	mean	of	
total	 number	 of	MLN	 cells	was	 detected	 in	 between	 different	
tested	groups	(Figure	6).	
	
	
	
Figure	 6. Determination	 of	 the	 total	 mean	 number	 of	 mesenteric	 lymph	
nodes	 lymphocytes	 of	 normal,	 vehicle	 and	 mice	 injected	 with	 single	 dose	
(100	mg/kg)	of	test	compounds	5a,	5b,	5c,	5d	and	5e.	
	
	
Conclusively,	 our	 humoral	 immunological	 study	 showed	
that	compound	5a	 and	5d	had	 immunostimulatory	responses.	
Interestingly,	 compound	 5a	 expressed	 a	 higher	 immune‐
stimulatory	 response	 than	 that	 of	 the	 vehicle.	 On	 the	 other	
hand,	 compound	 5b,	 5c,	 or	 5e	 had	 an	 immunosuppressive	
response	than	the	vehicle.	
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Table	3.	The	mean	of	the	total	number	of	lymphocyte	infiltrations	and	lymphocyte	aggregations	in	the	liver	sections	of	mice	injected	with	compounds	5a‐e.	
Aggregations,	mean±S.E.M	b		Infiltrations,	mean±S.E.M	a		Compound	
1.50±0.873.00±0.00	Normal	
0.75±0.482.00±1.00	Control	
1.20±1.564.00±1.08	5a	
0.25±0.195.00±0.41	5b	
0.00±0.00	7.00±4.00	5c	
1.00±0.31	3.50±1.44	5d	
2.00±1.006.33±1.67	5e	
a	 The	mean	 of	 the	 total	 number	 of	 lymphocyte	 infiltrations	 in	 the	 liver	 sections	 from	normal	mice	 or	mice	 injected	with	 compounds	5a,	5b,	5c,	5d	 and	5e,	
respectively.	
b	The	mean	of	 the	 total	number	of	 lymphocyte	 aggregations	 in	 the	 liver	 sections	 from	normal	mice	or	mice	 injected	with	 compounds	5a,	5b,	5c,	5d	 and	5e,	
respectively.	
	
	
Moreover,	mice	 injected	with	compound	5a,	5b,	5c,	5d	or	
5e	showed	an	increase	in	the	mean	of	the	total	number	of	MLN	
cells	as	compared	with	total	number	of	native	MLN	cells.	There	
was	no	significant	change	in	the	mean	of	total	number	of	MLN	
cells	from	each	compound	as	compared	with	the	other	one.	
	
3.2.2.4.	Microscopic	examination	of	liver	sections	
	
Liver	sections	 from	mice	 injected	with	compounds	5a,	5b,	
5c	and	5d	showed	small	lymphocytes	infiltration	around	blood	
vessels	 and	 lymphatic	 aggregations	 in	 hepatic	 parenchyma,	
which	were	the	predominant	microscopic	observations	(Figure	
7).	 Liver	 sections	 from	 mice	 injected	 with	 compound	 5e	
showed	 a	 large	 lymphocytes	 infiltrations	 as	 well	 as	
lymphocytes	 aggregations	 (Table	 3).	 There	was	 no	 significant	
change	 between	 the	 numbers	 of	 lymphocyte	 infiltrations	 or	
aggregations	in	the	liver	sections	of	vehicle,	5a,	5b,	5c,	5d	or	5e	
as	compared	with	normal	liver	sections	(Table	3).	Compounds	
5a‐e	 showed	 no	 hepatocytes	 degenerations.	 Our	 observation	
was	in	agreement	with	Amir	et	al.	[39],	whereas	the	derivatives	
of	 1,2,4‐triazolo‐[3,4‐b]‐1,3,4‐thiadiazole	 derivatives	 of	
ibuprofen	 and	 biphenyl‐4‐yloxy	 acetic	 acid	 do	 not	 show	 any	
significant	pathological	changes.		
	
	
	
Figure	7.	Histopathological	appearance	of	the	liver	sections	from	normal	or	
mice	injected	with	compound	5e.	Arrows	point	to	normal	hepatocytes	and	no	
lymphocyte	 infiltration;	 control	 liver	 [image	 a]	 and	 large	 lymphocyte	
infiltrations	and	lymphocyte	aggregations;	in	liver	section	from	mice	injected	
with	compound	5e	[images	b,	c,	and	d]	(Hematoxylin	and	eosin‐stain	200).	
	
	
4.	Conclusion	
	
In	summary,	the	well‐recognized	anticonvulsant	activity	of	
thiadiazole	 and	 hydrazinecarboxamide	 pharmacophores	 has	
been	 emphasized	 and	 compared	 with	 newly	 synthesized	
compounds	 5a‐e.	 These	 compounds	 5a‐e	 could	 be	 used	 to	
foster	 the	 anticonvulsant	 activity	 of	 other	 week	 antiepileptic	
drugs.	On	 the	 other	 hand,	new	 activity	 as	 immunomodulators	
has	been	discovered	for	the	investigated	compounds	5a‐e.	
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